In this article, we discuss some of the current research that has come out in regards to CBD oil for Alzheimer's Disease, in the hopes of. CBD Health Benefits for DementiaAlzheimer's DiseaseVascular core cause of Alzheimer's symptoms can often be reduced by using CBD oil. Before we get looking at CBD oil for Alzheimer's disease though, is CBD oil exactly, and should you use it as a practical treatment option?.
Oil Is it for CBD Practical Treatment? Disease: Alzheimers a
When we went to the oral dose, then it was more controlled, and instead of him eating it constantly, it was measured out periodically three times a day. That worked out a lot better, and he was able to establish evenness towards his improvement. Over time, he was reintegrated into a system, his own natural system seemed to be starting to work again, and he was showing significant recovery in many areas, but, again, not everything was cured. I have a question too.
Perhaps someone is watching that is not really familiar with vaporizing and the process of that, so could you explain that? We know, of course, it comes from smoking marijuana. A drug that comes in through the airway can be easily gotten into the blood, and then that blood typically goes to the brain immediately, so you have the cognitive effects, the brain effects, and neurologic modulation that occur right away.
The molecules are very, very similar. What happens in the E-cigarette, let me get back to that topic, the oil is in a chamber. A few inhalations of that will allow you to get the cannabidiol right to the brain and the rest of the body. How much more efficient is it and how much less can you use vaping versus non-vaping? My other question is—the new product in the dropper bottle, can that be vaped?
It needs to be in the right blend, and the blend contains propylene glycol and vegetable glycerin, and that helps it vaporize and it is more easily absorbed that way. It strictly is a different modality. Which one is more effective? You asked about the absorption. Vaping seems a little difficult for most people. My clients, I just have them do it sublingually and hold it in there for five or ten minutes. It worked, but it is more difficult. Daniel that syringe style may be going out.
The X-pen delivers a standard dose of 15 mg consistently. Out that old syringe, just for my people who have the syringe, if you put the little line like a rice grain on your finger, how many milligrams is that? I go by the size of a pea. I have people make a little bit of pea. The size of a pea—how many milligrams is that? I think you told me that a long time ago. That can be very effective for people, just using those very small amounts.
Starting with incremental dosage on the order of mg three times a day, is a great place to start, and then you can make adjustments from there. In those severe problems where people are manifesting huge metabolic issues or chronic diseases and severe pain, then it may be that we need to move up to 45 mg three times a day or 90 mg a couple times a day. The pharmacokinetics of CBD say that it lasts 24 hours in the bloodstream, but I think typically the response that I have seen is on the order of 8 hours feeling those particular effects.
It could be a lesser amount at one time and a higher amount or supplement to go along with it if there is an exacerbation excitement as you were having, Daniel, with your flying and some additional pain you had, then you might increase the dose temporarily and have a supplemental dose. When we put it in the mouth, we like to utilize some MCT oil just to help that absorption, and, again, up the percentages.
Do you have any recommendations there? Certainly, in swallowing it, I think the MCT oil helps, and then the MCT oil makes it a much more pleasant experience and those concentrates are rather strong. Any of the fats are going to be good, because CBD is fat soluble, and it likes to mix with fat.
Will it enhance the absorption? It should not matter. You can eat afterwards. You can imagine that the CBD causes a certain amount of relaxation; well it may be that the lower esophageal sphincter gets relaxed in that process too.
I have two questions that I have had. I see a thought process. I see a more socialization, and I see more humor. These are things that family members can observe. I also had a patient who stated they loved the results. How would you answer that? People stop smoking after using cannabidiol.
It has an improvement and a reduction in withdrawal, and yet combined with the highest level of narcotics it has not produced any increase in respiratory depression.
Can I ask one more question though? Would it replace the medications in a lot of ways? I think that it will reduce the amount of medications that they may need. We do see a blood pressure lowering and a relaxation of blood vessels, so they may not need as much of their other medications.
We can have that on a future show too. Maybe we can do a part three on CBD oil and the benefits in the bedroom. Maybe we can call it that. It is a subtle finding. Thanks for getting up early. Yes, thank you Dr. This was such a wealth of information. We have this new website where you can order it. Thanks again, everyone, for watching. Pompa and I will be sharing the top 10 strategies to avoid holiday weight gain, which is a hot topic with Thanksgiving, Christmas, and all the holidays coming up.
We are an authorized provider for the Member Share Network. Services are limited to members. Ask us about free membership!
The entire contents of this website are based upon the opinions of Dr. D, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as noted. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice.
It is intended as a sharing of knowledge and information from the research and experience of Dr. Pompa and his associates. Pompa encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional.
Menu Skip to right header navigation Skip to primary navigation Skip to content Skip to primary sidebar Skip to footer. Top 5 Health Strategies Series: Transcript of Episode Is my sound alright? This is the oil, and we have the tincture as well. How much was he taking? What was his dosage? Three times a day.
By applying these same properties to the brain, it would appear that CBD could be effective at helping promote healthy brain cell regeneration as well. Jonathan Miller, age 53 is an Ex Railyard Engineer who suffers from chronic back pain and anxiety.
How Do They Stack Up? Can it Regenerate Damaged Nerves? A Perfect Molecular Matchup? Revelation… or Total Gimmick? E-liquid — Which is Healthier?
Cannabinoids have been studied for alleviation of hyperkinetic symptoms, given their inhibitory effects on movement, and, in particular, as disease-modifying agents due to their anti-inflammatory, neuroprotective and neuroregenerative properties.
The article presents some promising patents on the cannabinoids. Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention? Alzheimer's disease has become a growing socio-economical concern in developing countries where increased life expectancy is leading to large aged populations.
While curing Alzheimer's disease or stopping its progression does not appear within reach in a foreseeable future, new therapies capable of delaying the pathogenesis would represent major breakthroughs.
The growing number of medical benefits of cannabinoids, such as their ability to regulate age-related processes like neuroinflammation, neurogenesis and memory, raise the question of their potential role as a preventive treatment of AD. To test this hypothesis, epidemiological studies on long term, chronic cannabinoid users could enlighten us on the potential benefits of these compounds in normal and pathological ageing processes.
Systematic pharmacological and thus more mechanistic investigations using animal models of Alzheimer's disease that have been developed would also allow a thorough investigation of the benefits of cannabinoid pharmacotherapy in the pathogenesis of Alzheimer's disease. The chronic administration of non-selective cannabinoids may delay the onset of cognitive deficits in AD patients; this will dramatically reduce the socio-economic burden of AD and improve the quality of life of the patients and their families.
Medicinal Plants and Dementia Therapy: Herbal Hopes for Brain Aging? An escalating "epidemic" of diseases like Alzheimer's has not yet been met by effective symptomatic treatments or preventative strategies. Among a few current prescription drugs are cholinesterase inhibitors including galantamine, originating from the snowdrop. Research into ethnobotanicals for memory or cognition has burgeoned in recent years. Based on a multi-faceted review of medicinal plants or phytochemicals, including traditional uses, relevant bioactivities, psychological and clinical evidence on efficacy and safety, this overview focuses on those for which there is promising clinical trial evidence in people with dementia, together with at least one other of these lines of supporting evidence.
With respect to cognitive function, such plants reviewed include sage, Ginkgo biloba, and complex mixtures of other traditional remedies. Behavioral and psychological symptoms of dementia BPSD challenge carers and lead to institutionalization. Symptoms can be alleviated by some plant species e. The ultimate goal of disease prevention is considered from the perspective of limited epidemiological and clinical trial evidence to date.
The potential value of numerous plant extracts or chemicals e. Given intense clinical need and carer concerns, which lead to exploration of such alternatives as herbal medicines, the following research priorities are indicated: The objective of this review is to summarize the current data on the use of antidepressants in the treatment of behavioral and psychological symptoms of dementia BPSD and to determine whether these medications can be recommended for routine clinical use.
The antidepressant drug was well tolerated in at least 14 of the 19 trials with information about tolerability in one trial not provided in the study paroxetine or placebo for FTD. This review indicates that antidepressants can be an effective in the treatment of BPSD and are generally well tolerated in elderly demented patients. Antidepressants for agitation and psychosis in dementia.
Agitation and psychosis are common among older adults with dementia and are challenging to manage. At the present time, little is known about the efficacy and safety of antidepressant medications when used to treat these symptoms. To assess the safety and efficacy of antidepressants in treating psychosis and agitation in older adults with Alzheimer's disease, vascular, or mixed dementia. Randomized, controlled trials of antidepressants selective serotonin reuptake inhibitors SSRIs , tricyclic antidepressants, trazodone, and other antidepressants , compared to either placebo or comparator medications typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications for treatment of agitation or psychosis in older adults with dementia.
Two authors independently assessed trial quality and extracted trial data. We collected information on efficacy as measured by dementia neuropsychiatric symptom rating scales and adverse effects.
Study authors were contacted for additional information. Nine trials including a total of individuals were included in the review. There was a significant difference between antidepressants and placebo on measures of agitation as reported on the change in CMAI total score mean difference MD , There were no significant differences in change in behavioral symptoms of dementia for SSRIs compared to placebo in the one study that reported on changes in the Neuropsychiatric Inventory and Behavioral Pathology in Dementia scales.
There was no difference in the rates of trial withdrawals due to adverse events for SSRIs compared to placebo for four studies reporting this outcome relative risk RR , 1.
One study compared the SSRI citalopram to the atypical antipsychotic risperidone and found no difference in NBRS scores, trial withdrawals due to any cause or trial withdrawals due to adverse events although the rates of adverse events as measured on the UKU side effect scale total score were lower for citalopram MD Three studies compared SSRIs to typical antipsychotics.
In meta-analysis of two studies there was no statistically significant differences in changes in CMAI total scores MD, 4. There was also no difference in trial withdrawals due to any cause or due to adverse events for SSRIs compared to typical antipsychotics.
One study of trazodone compared to placebo did not find any significant difference in change in CMAI total scores MD, 5. Two studies comparing trazodone to haloperidol also failed to detect any difference in change in CMAI total scores MD, 3. Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia. The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.
Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics. Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.
The dual neuroprotective—neurotoxic profile of cannabinoid drugs. Feb Br J Pharmacol. Extensive in vitro and in vivo studies have shown that cannabinoid drugs have neuroprotective properties and suggested that the endocannabinoid system may be involved in endogenous neuroprotective mechanisms.
On the other hand, neurotoxic effects of cannabinoids in vitro and in vivo were also described. Several possible explanations for these dual, opposite effects of cannabinoids on cellular fate were suggested, and it is conceivable that various factors may determine the final outcome of the cannabinoid effect in vivo. Indeed, our recent findings support this assumption and show that a pre- or a postconditioning treatment with extremely low doses of THC, several days before or after brain injury, provides effective long-term cognitive neuroprotection.
The future therapeutical potential of these findings is discussed. Cannabidiol CBD , one major non-psychotomimetic compound of the cannabis sativa plant, has shown anxiolytic effects both in humans and in animals. Each volunteer participated in only one experimental session in a double-blind procedure. The results were submitted to a repeated-measures analysis of variance.
Pretreatment with CBD significantly reduced anxiety, cognitive impairment and discomfort in their speech performance, and significantly decreased alert in their anticipatory speech. The placebo group presented higher anxiety, cognitive impairment, discomfort, and alert levels when compared with the control group as assessed with the VAMS. A Review of Clinical and Preclinical Data. The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia.
We review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: Numerous studies have demonstrated an involvement of the cannabinoid system in neurotransmission, neuropathology and neurobiology of dementias. In addition, several candidate compounds have demonstrated efficacy in vitro. However, some of the substances produced inconclusive results in vivo.
Therefore, only few trials have aimed to replicate the effects seen in animal studies in patients. Indeed, the literature on cannabinoid administration in patients is scarce. While preclinical findings suggest causal treatment strategies involving cannabinoids, clinical trials have only assessed the suitability of cannabinoid receptor agonists, antagonists and cannabidiol for the symptomatic treatment of dementia.
Further research is needed, including in vivo models of dementia and human studies. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. Cognitive deficits that persist up to a month have been detected among adult marijuana users, but decrements and their pattern of recovery are less known in adolescent users.
In this longitudinal study, we characterized neurocognitive changes among marijuana-using adolescents across the first three weeks of abstinence. Participants completed a brief neuropsychological battery on three occasions, after 3days, 2weeks, and 3weeks of stopping substance use. Abstinence was ascertained by decreasing tetrahydrocannabinol metabolite values on serial urine drug screens.
Verbal learning, verbal working memory, attention and vigilance, and time estimation were evaluated. Improvements in users were seen on word list learning after 2weeks of abstinence and on verbal working memory after 3weeks. While attention processing speed was similar between groups, attention accuracy remained deficient in users throughout the 3-week abstinence period.
This preliminary study detected poorer verbal learning and verbal working memory among adolescent marijuana users that improved during three weeks of abstinence, while attention deficits persisted. These results implicate possible hippocampal, subcortical, and prefrontal cortex abnormalities.
What are the specific vs. Generalized effects of drugs of abuse on neuropsychological performance? Most substance abusers simultaneously use and abuse more than one substance, even when there is a clear drug of choice. This pattern creates a great challenge in relating neuropsychological findings in drug users to a certain drug. This review aims to: We review evidence from human studies in chronic substance abusers using three methodologies: Converging evidence from these approaches indicates that all the drugs studied are commonly associated with significant alterations in the neuropsychological domains of episodic memory, emotional processing, and the executive components of updating and decision-making.
However, there is evidence of a greater reliability in the association of certain substances with specific neuropsychological domains. Specifically, there are relatively more robust effects of psychostimulants and alcohol use on impulsive action and cognitive flexibility, of alcohol and MDMA use on spatial processing, perceptual speed and selective attention, cannabis and methamphetamine on prospective memory deficits, and cannabis and MDMA on processing speed and complex planning.
The magnitude of both generalized and specific neuropsychological effects is overall attenuated in samples achieving long-term abstinence, but there are persistent psychostimulant-related effects on updating, inhibition, flexibility and emotional processing, and opioid-related effects on updating and decision-making.
Psychotropic medications are commonly administered to elderly clients to manage behavior and psychiatric symptoms.
These drugs are known to have potentially serious side effects, to which older adults are more vulnerable. Nurses care for older adults in many different practice settings but have varying degrees of knowledge about these kinds of medications. The purposes of this article are to a provide information to geriatric nurses in all settings about how the most commonly prescribed psychotropic medications i.
Chronic Pain Management in Older Adults: The rising prevalence of neuropathic pain and the multifaceted sequelae of pain particularly within older adults are part of the increasing challenges in providing good geriatric pain management. Aging can lead to a higher sensitivity to pain within older adults, whereas physiological changes modify the absorption, bioavailability, and transit time of pharmaceutical agents.
Ultimately, these differences within older adults require clinicians treating them to provide individually tailored analgesic approaches. Progressive age increases the variance in physiology among people; thus, the management approach should reflect an individual's unique requirements and limitations based on findings at the time of assessment. Cannabinoids for the treatment of dementia.
Cannabinoids are compounds derived from the cannabis plant Cannabis sativa. Laboratory studies have indicated that cannabinoids may regulate some of the processes that lead to neurodegeneration. This suggests that cannabinoids could be useful in the treatment of neurodegenerative dementias such as Alzheimer's disease.
So far, only one small randomized controlled trial has assessed the efficacy of cannabinoids in the treatment of dementia. This study had poorly presented results and did not provide sufficient data to draw any useful conclusions. May Psychol Med. Recent work suggests that heavy use of cannabis is associated with an increased risk of schizophrenia-like psychosis.
However, there is a dearth of experimental studies of the effects of the constituents of cannabis, such as Delta9-tetrahydrocannabinol THC. In a study of intravenous i. THC-induced positive psychotic symptoms, and participant- and investigator-rated measurements of these were highly correlated.
Participants showed an increase in anxiety ratings but there was no relationship between either self- or investigator-rated positive psychotic symptoms and anxiety. These findings confirm that THC can induce a transient, acute psychotic reaction in psychiatrically well individuals. The extent of the psychotic reaction was not related to the degree of anxiety or cognitive impairment. A Promising Drug for Neurodegenerative Disorders?
Neurodegenerative diseases represent, nowadays, one of the main causes of death in the industrialized country. They are characterized by a loss of neurons in particular regions of the nervous system.
It is believed that this nerve cell loss underlies the subsequent decline in cognitive and motor function that patients experience in these diseases. A range of mutant genes and environmental toxins have been implicated in the cause of neurodegenerative disorders but the mechanism remains largely unknown. At present, inflammation, a common denominator among the diverse list of neurodegenerative diseases, has been implicated as a critical mechanism that is responsible for the progressive nature of neurodegeneration.
Since, at present, there are few therapies for the wide range of neurodegenerative diseases, scientists are still in search of new therapeutic approaches to the problem.
An early contribution of neuroprotective and antiinflammatory strategies for these disorders seems particularly desirable because isolated treatments cannot be effective.
In this contest, marijuana derivatives have attracted special interest, although these compounds have always raised several practical and ethical problems for their potential abuse. Nevertheless, among Cannabis compounds, cannabidiol CBD , which lacks any unwanted psychotropic effect, may represent a very promising agent with the highest prospect for therapeutic use.
Neuropsychiatric symptoms in dementia: Importance and treatment considerations. Sep Int Rev Psychiatr. Neuropsychiatric symptoms are frequent in people with dementia, result in distress for the people experiencing them and their caregivers, and are a common precipitant of institutional care.
The safe and effective treatment of these symptoms is a key clinical priority, but is a long way from being achieved. Psychological interventions are recommended as the first line treatment strategy in most good practice guidelines, and there is emerging evidence of efficacy for agitation and depression.
Neuroleptics remain the mainstay of pharmacological treatment, although meta-analyses indicate that they are mainly of benefit for the short-term up to 12 weeks treatment of aggression in people with Alzheimer's disease, and there have been increasing concerns about serious adverse effects including mortality.
The Use of Cannabinoids in Treating Dementia
As a form of dementia, Alzheimer's disease wreaks havoc with a However, new Alzheimer's treatments, such as cannabis oil, may slow the. Episode CBD Oil and Alzheimer's Disease In this episode, Dr. you managed workers injuries and provided primary care above the I believe it's from a practical standpoint that I've evolved into this, and cannabidiol is. New ways to treat the neurodegenerative disease have been introduced in recent Cannabis shows promise in treating Alzheimer's symptoms The researchers concluded that “adding medical cannabis oil to Alzheimer's patients' .. (University Health Network) to oversee all good production practice. X.